Lineus Medical Awarded Five Additional Patents

FAYETTEVILLE, Ark. - April 3, 2025 - PRLog -- Lineus Medical has been granted five additional international patents for its flagship product, SafeBreak® Vascular, in Korea, Brazil, Australia, India, and China. These patents strengthen Lineus Medical's intellectual property portfolio as the company continues expanding into major healthcare markets worldwide. They also mark a key milestone toward obtaining regulatory clearances and establishing distribution partnerships in these regions.

SafeBreak Vascular is the only break-away device for IV lines clinically proven to reduce IV complications¹. When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money¹.

"Securing these new patents is a critical step in advancing the global presence of SafeBreak," said Vance Clement, CEO of Lineus Medical. "They not only protect our product from being copied and add value to the company, they also provide us credibility in establishing relationships with new distribution partners in these countries."

About Lineus Medical:

Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications¹. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.

References:

1.      Data on File

Photos: (Click photo to enlarge)




Source: Lineus Medical

Read Full Story - Lineus Medical Awarded Five Additional Patents | More news from this source

Press release distribution by PRLog